1-6 of 6
Tong Shen
Close
Sort by
Journal Articles

A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease

Yang Dai, Kelley Hill, Daniel Harris, Tong Shen, Chao-Xing Yuan, Christoph Gasteyger
Journal: Blood
Blood (2022) 140 (Supplement 1): 8298–8299.
https://doi.org/10.1182/blood-2022-166694
Published: 2022
Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Clinical Trials & Observations
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Journal: Blood
Blood (2021) 138 (1): 11–22.
https://doi.org/10.1182/blood.2020009098
Published: 2021
Includes: Supplemental data
Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137233
Published: 2020
Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Scott F Huntington, MD MPH, Stephen J. Schuster, MD, Wei He, PhD, Tong Shen, PhD, Heather Walker, MPH, CCRP, Laura Leary, Kylie Boyhen, Jennifer Gill, CRNP, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L. Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, Tanya Latorre, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, RN, Jakub Svoboda, MD, Victoria Addis, MD, Barry Douglas Anderson, MD PhD, Emily Leblond, Yuqin Song, MD PhD, Jun Zhu, MD PhD, Lijuan Deng, MD PhD, Danielle M. Brander, MD, Wei Ding, MD PhD, Allison C. Rosenthal, DO, Han Tun, MD, Anthony R. Mato, MD MSCE
Journal: Blood
Blood (2018) 132 (Supplement 1): 5384.
https://doi.org/10.1182/blood-2018-99-112944
Published: 2018
Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

William G. Wierda, MD PhD, Michael R. Bishop, MD, Olalekan O. Oluwole, MBBS, MPH, Aaron C. Logan, MD PhD, Maria R. Baer, MD, William B. Donnellan, MD, Kristen M. O'Dwyer, MD, Januario E. Castro, MD, Gary J. Schiller, MD, Houston Holmes, MD, Mehrdad Abedi, MD, Armin Ghobadi, MD, Martha L. Arellano, MD, Adriana K. Malone, MD, John M. Pagel, MD PhD, Armen Mardiros, PhD, Tong Shen, MS, Remus Vezan, MD PhD, Rajul K. Jain, MD, Bijal D. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 897.
https://doi.org/10.1182/blood-2018-99-111531
Published: 2018
Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 888.
https://doi.org/10.1182/blood.V130.Suppl_1.888.888
Published: 2017